Treatment of HIV infection with raltegravir

被引：0
|
作者：
Chirch, Lisa M. [1 ]
Morrison, Sidonie A. [1 ]
Steigbigel, Roy T. [1 ]
机构：
[1] SUNY Stony Brook, Sch Med, Div Infect Dis, Stony Brook, NY 11794 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2009年 / 10卷 / 07期
关键词：
antiretroviral therapy; HIV; human immunodeficiency virus; integrase inhibitor; raltegravir; INTEGRASE INHIBITOR RALTEGRAVIR; STRAND TRANSFER; PHARMACOKINETICS; TOLERABILITY; MK-0518; THERAPY; SAFETY; VIRUS;
D O I：
10.1517/14656560902911488
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus. Objective: To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability. Methods: Data from pharmacokinetic, Phase II and III clinical trials were reviewed. Results/conclusions: Results from clinical trials indicate that raltegravir is safe and highly effective in the treatment of both antiretroviral-naive and -experienced patients.
引用
收藏
页码：1203 / 1211
页数：9
相关论文
共 50 条
  • [1] Raltegravir: Its use in the Treatment of HIV Infection
    Harris, Marianne
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 183 - 197
  • [2] Raltegravir: first integrase inhibitor for the treatment of HIV infection
    Makinson, Alain
    Reynes, Jacques
    FUTURE VIROLOGY, 2009, 4 (01) : 23 - 34
  • [3] Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents
    Nuttall, James
    Meyers, Tammy
    Eley, Brian
    PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2013, 4 : 75 - 87
  • [4] Raltegravir In Treatment-Naive Patients with HIV-1 Infection
    Croxtall, Jamie D.
    Scott, Lesley J.
    DRUGS, 2010, 70 (05) : 631 - 642
  • [5] Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection
    Anker, Mary
    Corales, Roberto B.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (01) : 97 - 103
  • [6] A safety evaluation of raltegravir for the treatment of HIV
    de Miguel, Rosa
    Montejano, Rocio
    Stella-Ascariz, Natalia
    Arribas, Jose R.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (02) : 217 - 223
  • [7] Raltegravir, an HIV-1 integrase inhibitor for HIV infection
    Cabrera, Cecilia
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (08) : 885 - 898
  • [8] Raltegravir A Review of its Use in the Management of HIV Infection in Treatment-Experienced Patients
    Croxtall, Jamie D.
    Keam, Susan J.
    DRUGS, 2009, 69 (08) : 1059 - 1075
  • [9] Role of raltegravir in the management of HIV-1 infection
    Okeke, N. Lance
    Hicks, Charles
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2011, 3 : 81 - 92
  • [10] Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir
    Koelsch, Kersten K.
    Boesecke, Christoph
    McBride, Kristin
    Gelgor, Linda
    Fahey, Paul
    Natarajan, Ven
    Baker, David
    Bloch, Mark
    Murray, John M.
    Zaunders, John
    Emery, Sean
    Cooper, David A.
    Kelleher, Anthony D.
    AIDS, 2011, 25 (17) : 2069 - 2078
12345